Replies to post #42882 on Avid Bioservices Inc (CDMO)

[dia76ca]

Thoughtful post sunstar. Why would real shareholders bash their own stock many times a day, week after week? Someone wants to buy our shares cheaply! These bashers have their reasons...and they are not concerned about other investors!

[geocappy1]

Sunstar

I have been a staunch supporter of PPHM for approx 10 years and have significant holdings. I was very excited in seeing all the collaborations highlighted in the last PR as well as the Avid hirings.

What is your feelings about why we hadn;t heard about more of the details regarding the collaborations before now? It would seem to me that several of these are newsworthy. If not, surely more detail could have been mentioned in the conference calls.

To me, a staunch supporter, it appears that management has certainly under publicized much of its progress. Although it was nice to see the PR, as mentioned by someone else, it seemed too much info to be swiped over in one PR (Gates, NIAID, TMTI, Brazil, U.K., Duke, Microbicides, Malaria, CMV, etc., etc.

We have heard of less than 50%. of this progress. It could have been touted much more. If we were an established player I could see the slow play but we are kind of struggling for attention. What do you think?

[sixosix354]

I have held PPHM for 11 years now and have always supported them.For this I may be rewarded with a reverse stock split. That pisses me off to no end and I will not reward them for doing it. I will vote yes on everything but the prop 4 and incentives. Good luck longs, Sixosix

[TXDESERTFOX]

AMEN!

[cheynew]

I am a little perplexed by your and other shareholder's constant comments labeling anyone who questions management's actions "paid bashers." Is it so inconceivable that a shareholder might be angry that his investment and support of a company (many of us over a decade or more) has been apparently intentionally managed to require a reverse split? That a run over a dollar which might have been managed to regain NASDAQ compliance was sold into with shelf shares, thereby driving the stock price down from $1.13 to half that? The company line is that cash in the bank is needed, but wouldn't it have been in the company's interest to regain compliance and then issue the shelf shares? It appears to me, at least, that this was the game plan all along, and it wasn't a shareholder friendly game being played by management.

Maybe in the alternative, some here are "management shills" and are being used to promote, possibly naively, a plan that rewards management far beyond their level of entitlement to the exclusion of benefits drifting down to the lowly level of the shareholder who put up hard-earned cash to pay their salaries and the bills.

[realist1]

RE "The extensive current hiring is a leading indicator that the Peregrine program is about to expand"

Well, correct me if I am wrong, but if the reverse split goes through (and we have every reason to think that it will) PPHM will be flush with millions more available shares to dilute with. That would pay some salaries. PPHM knows dilution.

[sunstar]

Peregrine is at $3.40 per share moving up on news of Dr. Robert Garnick joining Peregrine as Head of Regulatory Affairs.

With twenty-four years experience and a senior vice president of regulatory, quality and compliance at Genentech, Dr. Garnick was responsible for the approval of 17 products including Rituxan, Herceptin, Avastin and Lucentis.

All three bavi phase 2 cancer trials are now fully enrolled. Now we wait as survival data develops. Objective responses were stellar in all three trials exceeding Avastin responses in all cases.

Safety has been great with bavi too. Avastin has been really horrible safety-wise including, but not limited to the development of holes in the stomach, small intestine, or large intestine, severe bleeding, or death.

Peregrine has also recently brought in cancer researcher Dr. Bruce Chabner as a clinical advisor to the company on the design of clinical trials for the bavituximab cancer program. Dr. Chabner is currently the clinical director of Massachusetts General Hospital (MGH) Cancer Center, chief of hematology and oncology at MGH and a professor of medicine at Harvard Medical School. Before coming to MGH, Dr. Chabner had a distinguished 25-year career at the National Cancer Institute (NCI), including serving as scientific director and director of the Division of Cancer Treatment.

These are two world class scientists whose expertise is focused on clinical trial design, implementation and successful completion. Their coming to Peregrine Pharmaceuticals at this point in time is another indicator that the company is at a threshold of expanded growth.

Peregrine is at an inflection point. We are at the end of three separate phase 2 cancer trials that will provide the first look at expanded numbers of patients with respect to safety and efficacy. We have already seen some superb results with bavituximab in these combination cancer trials. Now all three trials have finished enrolling. This is the statistical point where the value of a successfully advancing drug candidate soars with respect to partnering or buyout.

Here is a chart from the journal,Nature: “Avoiding Premature Licensing” that shows the inflection point with respect to stages of clinical trial phase development.

http://www.nature.com/nrd/journal/v5/n12/full/nrd2203.html



I’m really happy with the progress, and a price structure that begins to make the stock accessible to an expanded group of investors.

sunstar